Bioporto A/S
CSE:BIOPOR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.222
2.965
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioporto A/S
Bioporto A/S
Net Issuance of Common Stock
Bioporto A/S
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Net Issuance of Common Stock
kr81.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Net Issuance of Common Stock
-kr3.5B
|
CAGR 3-Years
-125%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Issuance of Common Stock
kr8.2B
|
CAGR 3-Years
123%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Issuance of Common Stock
€320.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Issuance of Common Stock
-kr660k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Net Issuance of Common Stock
kr17.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
81.4m
DKK
Based on the financial report for Jun 30, 2024, Bioporto A/S's Net Issuance of Common Stock amounts to 81.4m DKK.
What is Bioporto A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
1%
Over the last year, the Net Issuance of Common Stock growth was 76%. The average annual Net Issuance of Common Stock growth rates for Bioporto A/S have been -10% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
